Last update : 12/05/2024 | Version : 1 | ID : 74126
General | |
Identification | |
Detailed name | A non-interventional study to assess the hemoglobin level depending on the comorbidity index in chronic kidney disease (CKD) patients not on dialysis treated with Mircera® |
Sign or acronym | COMETE |
CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation | ML28145 |
General Aspects | |
Medical area |
Urology, andrology and nephrology |
Study in connection with Covid-19 |
No |
Pathology (details) | Chronic Kidney Disease not on dialysis |
Health determinants |
Iatrogenic Medicine |
Keywords | MIRCERA® |
Scientific investigator(s) (Contact) | |
Name of the director | Roche Medical Data Center |
Address | 4 cours de l'Ile Seguin - 92650 BOULOGNE-BILLANCOURT |
data_sharing_france@roche.com | |
Organization | Roche SAS |
Collaborations | |
Participation in projects, networks and consortia |
No |
Funding | |
Funding status |
Private |
Governance of the database | |
Sponsor(s) or organisation(s) responsible | Roche SAS |
Organisation status |
Private |
Presence of scientific or steering committees |
Yes |
Additional contact | |
Name of the contact | https://www.roche.fr/fr/innovation-recherche-medicale/data-sharing-portail-d-information-partage-des-donnees.html |
Main features | |
Type of database | |
Type of database |
Study databases |
Study databases (details) |
Cohort study |
Database recruitment is carried out by an intermediary |
A selection of health institutions and services |
Database recruitment is is made on the basis of: |
Medication(s) taken |
Database recruitment is carried out as part of an interventional study |
No |
Database objective | |
Main objective |
Primary objective : Describe in current medical practice the evolution of hemoglobin levels during the 9-month follow-up in each subgroup defined by the Charlson comorbidity index.
Secondary objectives : - Describe the characteristics of patients treated with Mircera® in the total population and in the subgroups defined by the Charlson comorbidity index; - Describe the evolution of the hemoglobin level during the observation period according to the Liu comorbidity index and to ESA resistance factors; - Describe the changes in the Mircera® dosage during the observation period in the total population and in the subgroups defined by the Charlson comorbidity index; - Describe the safety profile of Mircera® during the observation period in the total population and in the subgroups defined by the Charlson comorbidity index. |
Inclusion criteria |
Inclusion criteria :
- Patient >=18 years of age; - Patient with chronic kidney disease not on dialysis; - ESA-naive patients (not having received ESAs within the 6 months prior to inclusion); - Patients with hemoglobin level <10.0 g/dL at inclusion; - Patients for whom the treating physician has decided to initiate treatment with Mircera® for medical reasons prior to study start; - Patient having received both oral and written information about the study, without any objections for the use of his/her personal data. Non inclusion criteria : - Patients with functional renal transplant; - Patients participating in a clinical trial on anemia due to CKD. |
Population type | |
Age |
Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years) Elderly (65 to 79 years) Great age (80 years and more) |
Population covered |
Sick population |
Pathology | N18 - Chronic kidney disease |
Gender |
Male Woman |
Geography area |
National |
Data collection | |
Dates | |
Date of first collection (YYYY or MM/YYYY) | 2012 |
Date of last collection (YYYY or MM/YYYY) | 2015 |
Size of the database | |
Size of the database (number of individuals) |
[500-1000[ individuals |
Details of the number of individuals | 550 |
Data | |
Database activity |
Data collection completed |
Type of data collected |
Clinical data Biological data |
Clinical data (detail) |
Medical registration |
Details of collected clinical data | Validation of inclusion and exclusion criteria - Dates of visits (or data of last contact with the patient) - Demographic - CKD history and evolution - Comorbidities - Most recent clinical and biological data - Previous and/or ongoing CKD treatments - Other specific treatments - Previous and/or ongoing anemia treatments - Treatment with Micera® - Adverses events - Reason for early study discontinuation. |
Presence of a biobank |
No |
Health parameters studied |
Health event/morbidity Health event/mortality Health care consumption and services |
Care consumption (detail) |
Medicines consumption |
Procedures | |
Data collection method | eCRF |
Classifications used | CDISC |
Quality procedure(s) used | GCP/GVP |
Participant monitoring |
Yes |
Monitoring procedures |
Monitoring by contact with the referring doctor |
Links to administrative sources |
No |
Promotion and access | |
Promotion | |
Access | |
Dedicated website | https://www.roche.fr/fr/innovation-recherche-medicale/data-sharing-portail-d-information-partage-des-donnees.html |
Presence of document that lists variables and coding procedures |
Yes |
Access to aggregated data |
Access on specific project only |
Access to individual data |
Access on specific project only |
Partners - FAQ - Contact - Site map - Legal notices - Administration - Updated on December 15 2020 - Version 4.10.05